We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

326 hedge funds and large institutions have $5.42B invested in Bio-Rad Laboratories Class A in 2018 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 109 increasing their positions, 126 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 29

12% more capital invested

Capital invested by funds: $4.82B → $5.42B (+$602M)

3% more funds holding

Funds holding: 316326 (+10)

8% more call options, than puts

Call options by funds: $2.45M | Put options by funds: $2.28M

0.73% less ownership

Funds ownership: 78.3%77.57% (-0.73%)

13% less repeat investments, than reductions

Existing positions increased: 109 | Existing positions reduced: 126

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

Holders
326
Holders Change
+10
Holders Change %
+3.16%
% of All Funds
7.46%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
40
Increased
109
Reduced
126
Closed
29
Calls
$2.45M
Puts
$2.28M
Net Calls
+$172K
Net Calls Change
+$2.07M
Name Holding Trade Value Shares
Change
Change in
Stake
Susquehanna International Group
226
Susquehanna International Group
Pennsylvania
$478K +$457K +1,656 New
OAM
227
Oppenheimer Asset Management
New York
$475K -$13.3K -48 -3%
QC
228
Quadrature Capital
United Kingdom
$441K +$422K +1,528 New
Royal Bank of Canada
229
Royal Bank of Canada
Ontario, Canada
$438K +$203K +735 +94%
Creative Planning
230
Creative Planning
Kansas
$427K +$1.93K +7 +0.5%
SCM
231
Shelton Capital Management
Colorado
$412K
UAS
232
United Asset Strategies
New York
$411K
Truist Financial
233
Truist Financial
North Carolina
$410K +$392K +1,420 New
LIA
234
LS Investment Advisors
Michigan
$407K +$6.63K +24 +2%
MC
235
Menta Capital
California
$399K -$15.7K -57 -4%
FCM
236
Flinton Capital Management
Pennsylvania
$392K
SAM
237
Shell Asset Management
Netherlands
$392K +$376K +1,360 New
HighTower Advisors
238
HighTower Advisors
Illinois
$371K +$43.9K +159 +14%
GCA
239
Gideon Capital Advisors
New York
$357K -$304K -1,101 -47%
PAM
240
Panagora Asset Management
Massachusetts
$352K
ZIM
241
Zacks Investment Management
Illinois
$346K +$331K +1,198 New
HS
242
HighVista Strategies
Massachusetts
$346K +$331K +1,200 New
VF
243
Virtu Financial
New York
$340K +$326K +1,180 New
Zurich Cantonal Bank
244
Zurich Cantonal Bank
Switzerland
$336K
ICOM
245
Investment Counselors of Maryland
Maryland
$327K -$22.9K -83 -7%
SO
246
STRS Ohio
Ohio
$323K +$309K +1,120 New
CMBA
247
C.M. Bidwell & Associates
Hawaii
$320K -$665K -2,410 -68%
Jane Street
248
Jane Street
New York
$313K -$123K -447 -29%
CIBC Asset Management
249
CIBC Asset Management
Ontario, Canada
$312K +$9.66K +35 +3%
QI
250
QS Investors
New York
$291K

BIO Hedge Fund Activity: Q2 2018 in Review

326 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q2 2018, worth a combined $5.42B — up 12% from $4.82B a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new BIO positions and 29 closed out — a net gain of 11 holders — while 109 added to existing stakes and 126 trimmed.

The largest buyer was Millennium Management, adding an estimated $81.3M. The largest seller was HealthCor Management, exiting entirely with an estimated $25.7M sold.

  • 326 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q2 2018, up from 316 in Q1 2018.
  • Funds reported $5.42B of Bio-Rad Laboratories Class A stock for Q2 2018, up 12% quarter-over-quarter.
  • 40 funds opened new Bio-Rad Laboratories Class A positions in Q2 2018 and 29 closed out, a net change of +11 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q2 2018 was Millennium Management, an estimated $81.3M added.
  • The largest Bio-Rad Laboratories Class A seller in Q2 2018 was HealthCor Management, an estimated $25.7M sold.

Based on aggregated 13F filings for Q2 2018.